Trial in Progress: First Report of the Phase 1/2 Study of the Safety and Efficacy of CPO107, a Bispecific Agent Targeting CD20/CD47 in CD20 Expressing Non-Hodgkin Lymphoma (NHL) Skarbnik, A. P., Chen, F. L., Mountjoy, L., Myint, Z., Young, P. A., Whiteley, A. R., Novick, S., Su, J., Wang, Q., Romanko, K., Wang, X., Li, Y., Zhong, S., Song, L., Advani, R. H. AMER SOC HEMATOLOGY. 2022: 12059-12060

View details for DOI 10.1182/blood-2022-164746

View details for Web of Science ID 000893230305040